

Clinicopathological Characteristics and Prognosis of combined Hepatocellular Cholangiocarcinoma

Authors: Yue Li, Du He, Zi-Jian Lu, Xia-Fei Gu, Xiao-Yu Liu, Min Chen, Yin-Xia Tu, Yu Zhou, Gemma Owen, Xian Zhang, Dan Jiang

Corresponding author: Dan Jiang, Ph.D Department of Pathology, West China Hospital, Sichuan University, Chengdu, 610041, China
 Department of Pathology, Chengdu Shangjin Nanfu Hospital, Chengdu, 611700, China
 Email: danjiang@scu.edu.cn

Supplementary Table 1. Number of CD3⁺ T cells and CD8⁺ T cells in hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) regions in classical type carcinoma (n=49).

	HCC Median (IQR), number/HPF	CCA Median (IQR), number/HPF	Z	P-value
CD3 ⁺ T cells	10 (9-20)	10 (8.5-20)	-0.218	0.828
CD8 ⁺ T cells	8 (5-15)	7 (5-15)	-0.165	0.869

Abbreviation: IQR, interquartile range; HPF, high-power field. Z and P: comparison of HCC to CCA region.

Supplementary Table 2. COX univariate analysis of independent prognostic factors of the intermediate cell carcinoma (n=23).

Variable	Univariate	
	HR (95% CI)	P-value
Age		0.384
<60 years	Ref.	
≥60 years	0.640 (0.234-1.750)	
Gender		0.88
female	Ref.	
male	0.923 (0.329-2.589)	
Hepatitis B/C infection		0.497
Present	Ref.	
Absent	1.668 (0.381-7.309)	
Serum AFP level		0.012
<200ng/ml	Ref.	
≥200ng/ml	0.217 (0.066-0.712)	
Serum CA199 level		0.294
<37 U/ml	Ref.	
≥37 U/ml	1.650 (0.648-4.203)	
Tumor size		0.919
<5cm	Ref.	
≥5cm	1.048 (0.422-2.603)	
Lymph node involvement		0.766
Present	Ref.	
Absent	1.299 (0.232-7.264)	
TNM stage		0.399
II	Ref.	
III	0.237 (0.027-2.096)	
IV	0.946 (0.333-2.687)	
Local recurrence		0.29
Present	Ref.	
Absent	0.507 (0.144-1.785)	
Metastasis		0.2
Present	Ref.	
Absent	0.440 (0.125-1.545)	
HER2 expression		0.668
0~2+	Ref.	
3+	1.382(0.314-6.007)	
FGFR2 gene aberrations		0.496
Present	Ref.	
Absent	0.651(0.189-2.239)	

Abbreviation: HR, hazard ratio; CI, confidence interval; Ref, reference; AFP, alpha-fetoprotein; CA199, carbohydrate antigen 19-9; TNM Stage, Tumor, Node, Metastasis stage.